News

The PJ-01 development project will leverage Parabon’s Essemblix drug development platform to design macromolecules and nanoscale fabrication technology used in the production. The NSF grant program funds technology

Featuring a simple interface and flexibility, the EDI/HQ with AS2 Complete software enhances visibility of data errors, prevents chargebacks and decreases system monitoring time. The solution also has

The pharmaceutical company will leverage the platform for performance-based trial management processes, to track key performance indicators throughout the studies and monitor its strategic outsourcing model. PharmaPros strategic

Vaxfectin adjuvant has demonstrated to considerably increase the antibody and T-cell immune responses against antigens expressed from DNA vaccines in multiple animal models. The adjuvant will be used

Menactra vaccine prevents meningococcal meningitis and meningococcal diseases caused by Neisseria meningitidis’ strains A, C, Y and W-135, in individuals nine months of age to 55 years old.

Previously Milla held several senior positions within both pharmaceutical companies and the service sector, where he was responsible for both operational and corporate activities. CROMSOURCE chief executive officer

The study results include chronic lymphocytic leukemia (CLL), multiple myeloma (MM), indolent NHL and MCL lymphoid malignancies. Of the 43 abstracts, five include oral presentations, according to the

Gengos has served several companies and gained experience in areas such as corporate strategy, business development and transactions. ImmunoCellular founder and chief scientific officer John Yu said, "ImmunoCellular’s

The research will leverage the MolecularBreeding technology platform that offers new approach in developing vaccines targeting different HIV-1 strains. Altravax chief scientific officer Dr. Robert Whalen said the